Artelo Biosciences Inc Dossier
Qualitative Analysis
Business overview
Artelo Biosciences, Inc. (NASDAQ: ARTL) is a clinical-stage biopharmaceutical company focused on the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system (ECS). The company's pipeline is designed to address significant unmet needs in anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Its lead product candidates include ART27.13, a synthetic cannabinoid agonist targeting cancer-related anorexia; ART26.12, a novel, potent, and selective Fatty Acid Binding Protein 5 (FABP5) inhibitor being developed as a non-opioid treatment for pain; and ART12.11, a patented synthetic cannabidiol (CBD) cocrystal with enhanced bioavailability and pharmacokinetic properties.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Expansion of the clinical development of ART27.13 into the ophthalmology space, specifically targeting glaucoma.
Expected impact: Enables capital-efficient entry into the multi-billion dollar glaucoma market without dilutive equity raises.
Strategic partnership with BioAI company ScienceMachine to leverage machine learning and AI agent technology to analyze Artelo's large internal FABP datasets.
Expected impact: Accelerates the identification of novel mechanisms of action, clinical biomarkers, and prioritization of follow-on compounds from the FABP5 library.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Harnesses proprietary AI technology to analyze clinical and preclinical datasets for the FABP5 inhibitor platform, optimizing biomarker strategies and drug development precision [1.2.1].
Terms: Undisclosed